Clinical trials
Adult clinical trials
Below are recruiting adult clinical trials, each written for real people, not researchers. We’re tracking 3,746 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06554795RecruitingPhase 1/Phase 2
Testing DB-1419 for advanced solid tumors
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06555419RecruitingPhase 1
Nusinersen dosing study via flexible spinal catheter
This trial investigates how the drug nusinersen (Spinraza) enters the body when given through a small, flexible tube placed in the lower back (ThecaFlex DRx system). It aims to learn how the drug is processed in adults and children with spinal muscular atrophy, which could help make dosing more convenient.
Phoenix, ArizonaAges 3 years+ - NCT06555432Recruiting
Study of maribavir for CMV infection after transplant
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
SeoulAges 19 years+ - NCT06559306RecruitingPhase 3
Seltorexant for depression with insomnia symptoms
This trial tests if adding seltorexant to your current antidepressant can improve depression and sleep problems. It is for people with major depressive disorder who still have symptoms, especially insomnia, despite trying at least one antidepressant.
Birmingham, AlabamaAges 18–74 - NCT06564389RecruitingPhase 1
First-in-human study of PF-07832837 in healthy adults and eczema patients
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
Anaheim, CaliforniaAges 18–70 - NCT06549790RecruitingPhase 1
Study of NMS-03597812 for relapsed or refractory AML
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06554509RecruitingPhase 2/Phase 3
Study of SHR-1819 for prurigo nodularis
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06555029Recruiting
Oral health help for older adults on Medicaid
This trial is testing an oral health program offered during routine primary care visits for older adults (55+) on Medicaid. It aims to see if adding dental care support to regular check-ups can improve health.
Cleveland, OhioAges 55 years+ - NCT06555939Recruiting
Resilience program for teens and young adults with sickle cell disease
This study tests a program called PRISM that helps teens and young adults with sickle cell disease build resilience and manage stress, anxiety, or depression. You may be eligible if you have sickle cell disease and feel down or worried.
Boston, MassachusettsAges 8–25 - NCT06565663Enrolling by invitation
Decision aid for gender-affirming surgeries
This study tests an online decision tool for people considering metoidioplasty or phalloplasty. The tool helps patients compare surgical options to make informed choices.
Hanover, New HampshireAges 18 years+ - NCT06561074RecruitingPhase 2
Study of calaspargase, decitabine, and venetoclax for young T-cell cancer
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
Houston, TexasAges 1 month–21 years - NCT05580666RecruitingPhase 3
Lower death risk by adding azithromycin to HIV treatment
This Phase 3 study tests whether adding azithromycin helps people with advanced HIV disease live longer. You would start (or restart or adjust) HIV treatment within 4 weeks and may also receive azithromycin or a comparison approach to see if outcomes improve.
AbidjanAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT06548542RecruitingPhase 2
Targeted drug study for moderate to severe Crohn's disease
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Dothan, AlabamaAges 18–75 - NCT06533761RecruitingPhase 1
Eganelisib alone or with chemo for relapsed AML
This trial tests an experimental drug called eganelisib, either alone or with the chemotherapy drug cytarabine, for people with relapsed or refractory acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It aims to see if the drug is safe and can help control the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06532565RecruitingPhase 1
Study of GS-2121 alone or with other drugs for advanced solid tumors
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT06538480RecruitingPhase 4
Zopa retreatment study for recurrent respiratory papillomatosis
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
Atlanta, GeorgiaAges 18 years+ - NCT06538064Recruiting
Study of HyQvia for Adults with CIDP in Routine Care
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
Rancho Mirage, CaliforniaAges 18 years+ - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06549179Recruiting
Testing a tool to diagnose autism in adults
This study tests a new French questionnaire (AMSE) to see how well it can identify autism in adults who are seeking a first diagnosis. It may help you get a clearer answer about whether you have autism.
ParisAges 18 years+ - NCT06538766Recruiting
How focus instructions affect strength training and walking in older adults
This study tests whether different types of mental focus during strength training can improve walking ability in older adults. It may help find better ways to stay steady and prevent falls.
Monte de Caparica, AlmadaAges 18 years+ - NCT06532552RecruitingPhase 2
Comparing four drug combinations for older or unfit AML patients
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Suzhou, JiangsuAges 18 years+ - NCT05090943Recruiting
Adult tic disorder registry for patients in France
This study is a registry, meaning it collects information about adults with tic disorders over time. It may help researchers better understand tic disorders and improve future care.
Clermont-FerrandAges 18 years+
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adult?
- Yes. Clin2 currently lists 3,746 recruiting adult studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adult trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adult trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.